Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

What this study is about

The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is: Does an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity? Participants will either participate in one of three groups: * Nutrition: Participant will only have a regular follow-up with a registered dietician; * Nutrition + Semaglutide: Participants will start a new medication targeting obesity and will have a regular follow-up with a registered dietician; * Semaglutide: Participants will start a new medication targeting obesity.

Who can join (things the study team will check)

✅ You may be able to join if…

• Body mass index between 30 and 50 kg/m2;
• Stade 2 or 3 (S2 or S3) hepatic steatosis with or without liver fibrosis.

🚫 You may not be able to join if…

• Type 1 diabetes diagnosis;
• Alcohol consumption exceeding recommendations [>140 g/week (women) and >210 g/week (men)];
• Known chronic hepatic disease non-steatotic at the entry of the study (Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, viral hepatitis, auto-immune hepatitis, etc.);
• Pharmacological treatment targeting obesity active or ended in the last 3 months;
• Bariatric surgery;
• Gastro-intestinal pathologies (GI cancers, IBD, etc.);
• Capsulated probiotics consumption;
• Antibiotic treatment in the last 3 months;
• Pregnancy;
• Cirrhosis diagnosis (hepatic decompensation).

Where this trial is running

• Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Quebec, Canada

Who to contact

Tristan Rocheleau, RD., M.Sc. · 418-656-8711, #2681 · tristan.rocheleau.2@ulaval.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06764056.